Shares of Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) saw unusually-strong trading volume on Monday . Approximately 6,503,797 shares traded hands during trading, an increase of 382% from the previous session’s volume of 1,349,783 shares.The stock last traded at $2.33 and had previously closed at $2.00.

Several research analysts have issued reports on MRNS shares. Zacks Investment Research lowered shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, April 7th. Oppenheimer Holdings Inc. restated a “buy” rating on shares of Marinus Pharmaceuticals in a report on Tuesday, May 3rd. Stifel Nicolaus lowered shares of Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, June 13th. Royal Bank Of Canada lowered shares of Marinus Pharmaceuticals from an “outperform” rating to a “sector perform” rating and lowered their price target for the stock from $14.00 to $2.00 in a report on Tuesday, June 14th. Finally, Goldman Sachs Group Inc. lowered shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Tuesday, June 14th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Marinus Pharmaceuticals currently has an average rating of “Hold” and an average target price of $7.80.

The firm’s 50 day moving average is $2.60 and its 200-day moving average is $4.67. The company’s market capitalization is $43.11 million.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.04. Equities research analysts expect that Marinus Pharmaceuticals Inc. will post ($1.47) earnings per share for the current fiscal year.

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.